26th Jul 2006 13:09
BTG PLC26 July 2006 BTG plc: Results of AGM London, UK, 26 July 2006: BTG plc (LSE: BGC), the medical innovations company,is pleased to announce that at its Annual General Meeting on 26 July 2006 allresolutions were passed on a show of hands. The number of proxy votes lodged foreach resolution prior to the meeting was as follows: Total for*Resolution No. of % of votes vote 1. Report & Accounts 89,790,460 99.812. Remuneration report 88,213,382 99.553. Re-elect Sir Brian Fender 89,691,500 99.744. Re-elect Dr William Jenkins 89,865,935 99.865. Re-appoint auditors 89,526,438 99.496. Auditors' remuneration 89,786,173 99.777. Share option performance conditions 89,727,473 99.718. Rules of Performance Share Plan 84,665,308 94.099. Authority to allot shares 89,842,988 99.8410. Dis-application of pre-emption rights 89,845,221 99.85 *Excludes discretionary votes (continued from table above) Total against Votes withheldResolution No. of % of No. of votes vote votes 1. Report & Accounts 69,186 0.08 37,5422. Remuneration report 303,242 0.34 1,380,0573. Re-elect Sir Brian Fender 136,950 0.15 65,2804. Re-elect Dr William Jenkins 26,825 0.03 9705. Re-appoint auditors 339,719 0.38 8,4466. Auditors' remuneration 105,589 0.12 4,9207. Share option performance conditions 159,450 0.18 9,6508. Rules of Performance Share Plan 5,221,806 5.80 9,9659. Authority to allot shares 43,288 0.05 7,55110. Dis-application of pre-emption rights 37,156 0.04 8,976 In accordance with Listing Rule 9.6.2, certified copies of the resolutionspassed as special business at the Annual General Meeting will shortly beavailable for inspection at the UK Listing Authority's Document ViewingFacility, which is situated at: Financial Services Authority, 25 The NorthColonnade, Canary Wharf, London E14 5HS. As previously announced in the 2006 Annual Report & Accounts, with effect fromthe conclusion of the Annual General Meeting Malcolm Coster retired from theBoard of the Company. Ends Contact for further information: Andy Burrows, Director of Investor Relations +44 (0)20 7575 1741 About BTG BTG in-licenses, develops and commercialises pharmaceuticals and other medicaltechnologies. With a substantial and growing revenue stream of royalties andmilestone payments from out-licensed products, BTG continues to strengthen itspipeline of preclinical and clinical development programmes. Active in thefields of oncology, diseases of ageing, neuroscience, drug repositioning andmedical devices, BTG works from offices in London, Philadelphia and Osakathrough a global partner network of healthcare companies and researchorganisations. For further information, visit: www.btgplc.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
BTG